Medicus Pharma Ltd
medicuspharma.comWhat Do They Do?
Develops a microneedle drug candidate for skin cancers and drug candidates for prostate conditions, seeking pharmaceutical companies to partner on later development and commercialization.
10-K for FY2025, filed Mar 25, 2026We are a clinical stage, multi-strategy biotech company focused on advancing novel and potentially disruptive select therapeutic assets…View ↗
The Company is actively engaged in multiple countries spread over three continents and opportunistically identifies, evaluates, acquires…View ↗
Through our wholly owned subsidiary, SkinJect, we focus on the development of our in-licensed drug device combination product using novel…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 25, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 12, 2026
−$11.6MView ↗
- ▲ +88% (Loss)
- vs −$6.2M in Q2 FY2025
-
Sep 3, 2026
Signs Pfizer co-development and license agreement for CD228V
Pfizer granted worldwide licenses and will contribute development funding; Medicus retains control and responsibility for development costs.
Sources
8-K, filed Sep 3, 2026
On September 2, 2026, Medicus Pharma Ltd. (the "Company"), through its wholly owned subsidiary, Medicus Pharma Inc., entered into a…View ↗
-
Apr 24, 2026
Nasdaq warns Medicus is below its minimum bid-price requirement
The company has until October 19, 2026 to regain compliance.
Sources
8-K, filed Apr 24, 2026
In accordance with the Nasdaq Listing Rule 5810(c)(3)(A), the Company has a period of 180 calendar days, or until October 19, 2026, to…View ↗
Loading...
